EFFECTS OF RISEDRONATE ON BONE TURNOVER MARKERS IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN: COMPARISON OF TWO PROTOCOLS OF TREATMENT.

##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Vol. 87 No. 6 (2009): Issue Jun 2009

##plugins.themes.academic_pro.article.main##

Afef Bahlous
Kahena Bouzid
Héla Sahli
Department of Rhumatology La Rabta Hospital- Tunis
Slaheddine Sallami
Jaouda Abdelmoula
Department of Clinical Biochemistry Charles Nicolle Hospital- Tunis

Abstract

Aim : Bisphosphonates are powerful agents able to prevent bone loss. The objective of the study was to evaluate the efficacy and tolerability of risedronate once a week (35 mg) compared with risedronate 5 mg once daily in women with osteoporosis.
Methods: A randomized, double-blind, active-controlled study enrolled 102 postmenopausal women aged 66.5+7.5 years with osteoporotic fractures. All women received risedronate during 6 months. Group 1 (G1, n=51) received risedronate 5 mg once daily and group 2 (G2, n=51) received 35 mg once a week. Serum alkaline phosphatase (ALP), bone alkaline phosphatase (bone ALP), serum C-terminal telopeptide of type I collagen (CTX) were measured at
baseline, 3 months and 6 months after treatment in the two groups.
Results: We noted no significant difference in markers between women of the 2 groups. After 3 months, bone ALP and CTX decreased (respectively -22.1% and -47.6%) in the 2 groups with no significant difference between them. After 6 months study, bone ALP and CTX decreased respectively by -46.5% and -62.9% with no statistically significant difference between study groups for bone markers.
Conclusion: Our study found that treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. We didn’t find adverse events with the 35 mg once-a-week dose group compared to the once-daily dose group. Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose. This therapeutic protocol may  provide an alternative for patients who prefer once-a-week oral dosing.

Keywords:

Risedronate, bone markers, menopause, osteoporosis, fracture controlled trial, randomized trial

##plugins.themes.academic_pro.article.details##

References

  1. Choi HJ, Im JA, Kim SH. Changes in bone markers after onceweekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas 2008, doi : 10. 1016/j. maturitas. 2008.05.003.
  2. Matti JV, Minguella JF, Halse J et al. Effects of risedronate 5mg/d on bone density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-Month, parallel-group, Phase III Trial. Clin Ther 2007; 29:1937-49.
  3. Brown JP, Kendler DL, McClung MR et al. The efficacy and tolerability of Risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71:103-11.
  4. hooper MJ, Ebeling PR, Robets AP et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial Climacteric 2005; 8: 251-62.
  5. Eriksen EF, Melsen F, Sod E et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31:620-5.
  6. Delmas PD, McClung MR, Zanchetta JR et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008; 42:36-42.